Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 2Neurofibromatosis 2 1Neurofibromatoses 1Neoplasms by Histologic Type 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Breast Neoplasms 1

Interventions

Imatinib Mesylate 8venetoclax 6Cytarabine 5ponatinib 4nilotinib 4Azacitidine 4zosuquidar trihydrochloride 2fludarabine 2bosutinib 2RO6839921 2Decitabine 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2spartalizumab 1sabatolimab 1pulrodemstat besilate 1posaconazole 1pegfilgrastim 1lestaurtinib 1gilteritinib 1flumatinib 1enasidenib 1emvododstat 1blinatumomab 1asciminib 1Whole-Body Irradiation 1N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide 1Lenalidomide 1Immunotherapy, Adoptive 1Idarubicin 1IMC-EB10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myeloid × emvododstat × Clear all
NCT03761069 2022-02-02

Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias

PTC Therapeutics

Phase 1 Terminated
33 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡